Skye Bioscience, Inc. (SKYE): Operating Cash Flow
-$43.06M
Year ended 2025-12-31
-$38.81M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$43.06M | n/m | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | -$25.24M | n/m | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | -$13.95M | n/m | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | -$12.74M | n/m | 2024-03-22, From 2022-01-01 |
| 2021-12-31 | -$6.47M | n/m | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | -$6.05M | n/m | 2022-03-28, From 2020-01-01 |
| 2019-12-31 | -$6.03M | n/m | 2021-03-02, From 2019-01-01 |
| 2018-12-31 | -$3.94M | n/m | 2020-03-23, From 2018-01-01 |
| 2017-12-31 | -$3.33M | n/a | 2019-03-14, From 2017-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Skye Bioscience, Inc. (SKYE) | 2025-12-31 | -$43.06M | n/m |
| Biofrontera Inc. (BFRI) | 2025-12-31 | -$13.36M | n/m |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | -$12.35M | n/m |
| TuHURA Biosciences, Inc. (HURA) | 2025-12-31 | -$27.63M | n/m |
| Aptevo Therapeutics Inc. (APVO) | 2025-12-31 | -$25.59M | n/m |
| Talphera, Inc. (TLPH) | 2025-12-31 | -$11.36M | n/m |
| Veru Inc. (VERU) | 2025-09-30 | -$30.04M | n/m |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $322.0K | n/m |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | -$5.33M | n/m |
Compare SKYE, BFRI, NEUP, HURA side by side · Screen every company in Pharmaceutical Preparations ↗